CDEK
← All drugs Report issue

spartalizumab

mAbexperimental

Spartalizumab is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma. — Wikipedia

Clinical trial activity

63 trials · 24 clinical orgs · 0 marketing orgs

Phase 1
43
Phase 2
32
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 2011 (NCT01351103)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pdr001

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07157345Phase 1Oct 20, 2025Jiao Tong University
NCT05201066Phase 2Jan 2, 2023Novartis
NCT05210413Phase 1/Phase 2 (Phase 2)Apr 1, 2022Fondation ARC, National Cancer Institute, France, Novartis, University of Bordeaux
NCT05135845Phase 2Nov 30, 2021Assistance Publique - Hôpitaux de Paris
NCT04895748Phase 1Nov 18, 2021Novartis
NCT04802876Phase 2Apr 12, 2021Novartis, SOLTI Breast Cancer Research Group
NCT04699188Phase 1/Phase 2 (Phase 2)Feb 24, 2021Novartis
NCT04191421Phase 1/Phase 2 (Phase 2)Dec 1, 2020Emory University, EUSA, National Cancer Institute (NCI), National Institutes of Health (NIH), Novartis
NCT04581343Phase 1Oct 31, 2020Novartis, Pancreatic Cancer Action Network
NCT04544111Phase 2Sep 2, 2020Memorial Sloan-Kettering Cancer Center
NCT04390763Phase 2Aug 5, 2020Novartis
NCT04323436Phase 2Jun 15, 2020Novartis
NCT04294160Phase 1May 26, 2020Novartis
NCT04283526Phase 1Apr 30, 2020Novartis
NCT04261439Phase 1Apr 29, 2020Novartis
NCT04237649Early Phase 1 (Phase 1)Feb 28, 2020Novartis
NCT04213404Phase 1Jan 31, 2020National Taiwan University, Novartis
NCT04310397Phase 2Jan 29, 2020University of Texas at Houston
NCT03982134Phase 1Sep 1, 2019Novartis, University of Iowa
NCT04028245Early Phase 1 (Phase 1)Aug 31, 2019Columbia University, Novartis
Showing 20 of 63 trials
Page 1 / 4

Organizations

Research & Development (24)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit554432011
Harvard UniversityAcademic/Hospital2222017
University of UlsanAcademic/Hospital2212018
Yonsei UniversityAcademic/Hospital2212019
Assistance Publique - Hôpitaux de ParisAcademic/Hospital1112021
Columbia UniversityAcademic/Hospital1112019
Emory UniversityAcademic/Hospital1112020
EUSAFor profit1012020
Fondation ARCAcademic/Hospital1012022
Jiao Tong UniversityAcademic/Hospital1112025
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112020
National Cancer Institute, FranceGovernment1012022
National Cancer Institute (NCI)Government1012020
National Institutes of Health (NIH)Government1012020
National Taiwan UniversityAcademic/Hospital1112020
Paloma Pharmaceuticals, Inc.For profit1112015
Pancreatic Cancer Action NetworkAcademic/Hospital1112020
Seoul National UniversityAcademic/Hospital1112019
SOLTI Breast Cancer Research GroupAcademic/Hospital1112021
Stand Up To CancerAcademic/Hospital1012018
24 organizations
Page 1 / 2